HLS Therapeutics is an Etobicoke, Ontario pharmaceutical company focused on acquiring and commercializing late-stage and commercial-stage branded medicines across North America. Public company materials highlight a portfolio aimed at psychiatric disorders and cardiovascular disease, including products such as CLOZARIL and VASCEPA. The company works with originators and manufacturing partners to bring specialty medicines to market.